Of note, the translational inhibitor, eFT508, possesses a potent inhibitive effect on the cancer progression and metastasis by targeting PD-L1 mRNA translation, disclosing a new strategy for immunotherapy in PD-1/PD-L1 axis blocking. The gene discussed is PDCD1; the disease is cancer.